VolitionRX Limited (VNRX): Price and Financial Metrics


VolitionRX Limited (VNRX)

Today's Latest Price: $3.23 USD

0.03 (-0.92%)

Updated Oct 26 9:37am

Add VNRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

VNRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VNRX is 0 -- better than merely 8.77% of US stocks.
  • With a price/sales ratio of 6,652.69, Volitionrx Ltd has a higher such ratio than 99.82% of stocks in our set.
  • As for revenue growth, note that VNRX's revenue has grown 33.56% over the past 12 months; that beats the revenue growth of 86.1% of US companies in our set.
  • Stocks that are quantitatively similar to VNRX, based on their financial statements, market capitalization, and price volatility, are AUPH, VTVT, MRTX, ADVM, and RVNC.
  • VNRX's SEC filings can be seen here. And to visit Volitionrx Ltd's official web site, go to www.volition.com.

VNRX Stock Price Chart Interactive Chart >

Price chart for VNRX

VNRX Price/Volume Stats

Current price $3.23 52-week high $6.06
Prev. close $3.26 52-week low $2.22
Day low $3.16 Volume 28,870
Day high $3.24 Avg. volume 304,915
50-day MA $3.33 Dividend yield N/A
200-day MA $3.65 Market Cap 154.78M

VolitionRX Limited (VNRX) Company Bio


VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is based in Singapore.


VNRX Latest News Stream


Event/Time News Detail
Loading, please wait...

VNRX Latest Social Stream


Loading social stream, please wait...

View Full VNRX Social Stream

Latest VNRX News From Around the Web

Below are the latest news stories about Volitionrx Ltd that investors may wish to consider to help them evaluate VNRX as an investment opportunity.

VolitionRx's (VNRX) CEO Cameron Reynolds on Q2 2020 Results - Earnings Call Transcript

VolitionRx Limited (VNRX) Q2 2020 Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Scott Powell – Executive Vice President-Investor Relations Cameron Reynolds – President and Chief Executive Officer Conference Call Participants Mike Okunewitch – Maxim Group Mark Briedenbach – Oppenheimer & Company Bruce Jackson – The Benchmark...

SA Transcripts on Seeking Alpha | August 15, 2020

Registration for Sidoti's 2020 Fall Virtual Investor Conference is Now Open

Our Biannual Investor Conference has become a leading forum for small-cap companies to interface with investors specifically interested in the small-cap equities.

Yahoo | July 30, 2020

'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st

LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private ...

Yahoo | July 16, 2020

VolitionRx up big on encouraging COVID-19 test data

VolitionRx (VNRX) surges 74% premarket on the heels of the results from two proof-of-concept studies using its Nu.Q assays. Two independent cohorts of COVID-19 positive patients with quantitative nucleosome immunoassays were tested, and it was found that nucleosomes were highly elevated in plasma of severe COVID-19 patients relative to healthy control subjects,...

Seeking Alpha | July 14, 2020

Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today announced that results from two proof of concept clinical studies using its Nu.Q™ assays have been submitted for peer review and will be available on BIORXIV.ORG shortly. "Circulating Nucleosomes as potential prognostic markers for COVID-19 disease severity" .

Yahoo | July 14, 2020

Read More 'VNRX' Stories Here

VNRX Price Returns

1-mo 6.25%
3-mo -2.71%
6-mo -25.06%
1-year -45.71%
3-year 36.86%
5-year -25.75%
YTD -31.86%
2019 161.88%
2018 -38.44%
2017 -35.67%
2016 1.56%
2015 15.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9553 seconds.